All Journals > The Journal of Infectious Diseases > 15 March 2005 > C. trachomatis Resistance and Treatment Failures

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

Science Watch logo

JID Article Named "New Hot Paper" by ScienceWatch.com

Dr. Lauri Hicks' 2007 article on pneumococcal disease has been named a "hot new paper" by Thompson Reuters' ScienceWatch.com. Read a Q&A about the article with Dr. Hicks here. 

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in Grist
"Another symptom of swine flu: instant amnesia" May 11, 2009
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Read the veterinary literature on swine flu and you get a strong sense of what might be called vaccination treadmill: the hog industry is literally scrambling to generate new vaccines for the rapidly evolving flu strains that sweep through CAFOs. Writing in the Journal of Infectious Diseases [PDF] in 2008, Eileen Thacker and Bruce Janke of Iowa State University paint a stark picture: “A number of genetically diverse viruses are circulating in swine herds throughout the world and are a major cause of concern to the swine industry,” they write. “Influenza virus infections in swine and poultry are potential sources of viruses for the next pandemic among humans.”

Featured in New York Times
"Fear of a Swine Flu Epidemic in 1976 Offers Some Lessons, and Concerns, Today" May 8, 2009
Anti‐Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine‐Associated Guillain‐Barré Syndrome
Irving Nachamkin, Sean V. Shadomy, Anthony P. Moran, Nancy Cox, Collette Fitzgerald, Huong Ung, Adrian T. Corcoran, John K. Iskander, Lawrence B. Schonberger, and Robert T. Chen
Irving Nachamkin, a professor of pathology and laboratory medicine at the University of Pennsylvania, examined some 1976 vaccine that had been saved by a scientist in Texas. In a paper published last year in The Journal of Infectious Diseases, he and colleagues reported that mice given the vaccine made antibodies that reacted with gangliosides, which are components of nerve cells. An antibody attack on gangliosides is part of the disease mechanism of Guillain-Barré.

Featured in AFP
"Swine flu vaccine 'could be ready soon'" May 7, 2009
A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses
Mary A. Hoelscher, Neetu Singh, Sanjay Garg, Lakshmi Jayashankar, Vic Veguilla, Aseem Pandey, Yumi Matsuoka, Jacqueline M. Katz, Ruben Donis, Suresh K. Mittal, and Suryaprakash Sambhara
The vaccine Mittal created for the bird flu worked on three different strains isolated over a seven-year period and was described in papers for the Journal of Infectious Diseases and the journal Clinical Pharmacology and Therapeutics.

Featured in Newsweek
"The Path of a Pandemic" http://www.newsweek.com/id/195692
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Last year researchers from Iowa State University in Ames warned that pigs located in industrial-scale farms were being subjected to influenza infections from farm poultry, wild birds and their human handlers. Writing in The Journal of Infectious Diseases, Eileen Thacker and Bruce Janke said, "As a result of the constantly changing genetic makeup of individual influenza viruses in pigs, the U.S. swine industry is continually scrambling to respond to the influenza viruses circulating within individual production systems."

15 March 2005

Volume 191, Number 6
The Journal of Infectious Diseases 2005;191:917–923
© 2005 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2005/19106-0013$15.00
DOI: 10.1086/428290
MAJOR ARTICLE

Evaluation of Antimicrobial Resistance and Treatment Failures for Chlamydia trachomatis: A Meeting Report

Susan A. Wang,1

John R. Papp,1

Walter E. Stamm,2

Rosanna W. Peeling,4

David H. Martin,3 and

King K. Holmes2

1Centers for Disease Control and Prevention, Atlanta, Georgia; 2University of Washington, Seattle; 3Louisiana State University Medical Center, New Orleans; 4World Health Organization, Geneva, Switzerland

Each year, Chlamydia trachomatis causes 3 million new infections and results in more than $1 billion in medical costs in the United States. Repeat or persistent infection occurs in 10%–15% of women who are treated for C. trachomatis infection. However, the role played by antimicrobial resistance in C. trachomatis treatment failures or persistent infection is unclear. With researchers in the field, we reviewed current knowledge and available approaches for evaluating antimicrobial resistance and potential clinical treatment failures for C. trachomatis. We identified key research questions that require further investigation. To date, there have been no reports of clinical C. trachomatis isolates displaying in vitro homotypic resistance to antimicrobials, but in vitro heterotypic resistance in C. trachomatis has been described. Correlation between the results of existing in vitro antimicrobial susceptibility tests and clinical outcome after treatment for C. trachomatis infection is unknown. Animal models may provide insight into chlamydial persistence, since homotypic resistance against tetracycline has been described for Chlamydia suis in pigs. Evaluating C. trachomatis clinical treatment failures, interpreting laboratory findings, and correlating the 2 clearly remain extremely challenging undertakings.

Received 8 July 2004; accepted 14 October 2004; electronically published 11 February 2005.

Reprints or correspondence: Dr. Susan A. Wang, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Mailstop G‐37, 1600 Clifton Rd. NE, Atlanta, GA 30333 ().

Cited by

C. Bébéar, B. de Barbeyrac. (2009) Genital Chlamydia trachomatis infections. Clinical Microbiology and Infection 15:1, 4-10
Online publication date: 1-Feb-2009.
CrossRef
Pragya Srivastava, Rishein Gupta, Hem Chandra Jha, Rajneesh Jha, Apurb Rashmi Bhengraj, Sudha Salhan, Aruna Mittal. (2009) Serovar-specific immune responses to peptides of variable regions of Chlamydia trachomatis major outer membrane protein in serovar D-infected women. Clinical and Experimental Medicine 8:4, 207-215
Online publication date: 1-Jan-2009.
CrossRef
M Riduan Joesoef, Hillard S. Weinstock, Robert E. Johnson. (2008) Factors Associated With Recurrent Chlamydial Infection and Failure to Return for Retesting in Young Women Entering National Job Training Program, 1998???2005. Sexually Transmitted Diseases 35:4, 368-371
Online publication date: 1-May-2008.
CrossRef
Toshifumi Kurahashi, Hideaki Miyake, Yuzo Nakano, Masashi Shinozaki, Nobutoshi Oka, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Soichi Arakawa, Masato Fujisawa. (2007) A comparison of clinical features between chlamydial and non-chlamydial urethritis in men negative for gonococcal infection who attended a urological outpatient clinic in Japan. International Urology and Nephrology 39:3, 809-813
Online publication date: 30-Sep-2007.
CrossRef
Patricia Kissinger, Hamish Mohammed, Gwangi Richardson‐Alston, Jami S. Leichliter, Stephanie N. Taylor, David H. Martin, and Thomas A. Farley. (2005) Patient‐Delivered Partner Treatment for Male Urethritis: A Randomized, Controlled Trial. Clinical Infectious Diseases 41:5, 623-629
Online publication date: 1-Sep-2005.
Abstract-Full Text-PDF Version (101 kB)

  • The subject of this manuscript was discussed by the authors and other meeting participants (see meeting participant list in the Acknowledgments section) at the Chlamydia trachomatis Susceptibility Meeting in Atlanta, Georgia, which was convened and funded by the Centers for Disease Control and Prevention, on 30 October 2001. There were no other sources of funding for the meeting.

Back to Top
Close Popup